[Joint pain crises and chronic inflammatory-reactive phenomena: a unitary approach with proglumetacin].
Nineteen patients with acute joint pain and 12 patients with chronic rheumatic disorders were treated with 450 mg/day of proglumetacin for a period ranging between 15 and 30 days. The overall results revealed a satisfactory response to treatment, and tolerance was rated as "good" or "very good" in all patients.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007210:Indoleacetic Acids / Q000627:therapeutic use*; D007592:Joint Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D052256:Tendinopathy / Q000188:drug therapy
D007210:Indoleacetic Acids; C019541:proglumetacin
Crisi algiche articolari e fenomeni flogistico-reattivi cronici: un approccio unitario con la proglumetacina.